ASLAN Pharmaceuticals Limited

Equities

ASLN

US04522R2004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
0.54 ^USD	+9.98%		0.00%	+3.43%

Apr. 18	Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	MT
Apr. 17	Asian Equities Traded in the US as American Depositary Receipts Remain Flat in Wednesday Trading	MT

ASLAN Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2022

August 12, 2022 at 06:54 am EDT

ASLAN Pharmaceuticals Limited reported earnings results for the half year ended June 30, 2022. For the half year, the company reported net loss was USD 25.97 million compared to USD 12.15 million a year ago. Basic loss per share from continuing operations was USD 1.75 compared to USD 1 a year ago.

Latest news about ASLAN Pharmaceuticals Limited

Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	Apr. 18	MT
Asian Equities Traded in the US as American Depositary Receipts Remain Flat in Wednesday Trading	Apr. 17	MT
Financial, Telecoms Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday	Apr. 16	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	Apr. 15	MT
Asian Equities Traded in the US as American Depositary Receipts Fall in Friday Trading	Apr. 12	MT
ASLAN Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 12	CI
ASLAN Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 12	CI
Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	Apr. 11	MT
Tech, Auto Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading	Apr. 09	MT
Asian Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading, End Week Lower	Apr. 05	MT
Asian Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	Apr. 02	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	Apr. 01	MT
Asian Equities Traded in the US as American Depositary Receipts Nudge Lower in Thursday Trading	Mar. 28	MT
Asian Equities Traded in the US as American Depositary Receipts Flat in Tuesday Trading	Mar. 26	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading	Mar. 25	MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Lower in Friday Trading	Mar. 22	MT
Asian Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Mar. 21	MT
Asian Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading	Mar. 20	MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	Mar. 19	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Sharply Higher in Monday Trading	Mar. 18	MT
HC Wainwright Cuts ASLAN Pharmaceuticals Price Target to $9 From $17, Maintains Buy Rating	Mar. 18	MT
ADRs Slump; Hello Group Declines 22%	Mar. 14	DJ
Asian Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading	Mar. 14	MT
Piper Sandler Cuts ASLAN Pharmaceuticals' Price Target to $10 From $15, Maintains Overweight Rating	Mar. 13	MT
ADRs End Higher, ATRenew Inc. Climbs 26.9%	Mar. 12	DJ

Chart ASLAN Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. It is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The Company is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy for autoimmune disease. The Company is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.

Sector

Biotechnology & Medical Research

Calendar

2024-04-24 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.54 USD

Average target price

10 USD

Spread / Average Target

+1,751.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ASLAN PHARMACEUTICALS LIMITED	+3.43%	12.22M
VERTEX PHARMACEUTICALS INCORPORATED	-3.30%	102B
REGENERON PHARMACEUTICALS, INC.	+1.79%	96.07B
ARGENX SE	-1.34%	21.66B
BIONTECH SE	-18.35%	20.77B
GENMAB A/S	-8.33%	18.53B
WUXI APPTEC CO., LTD.	-40.31%	16.91B
BEIGENE, LTD.	-26.84%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.59%	13.33B
SAREPTA THERAPEUTICS, INC.	+20.86%	10.94B

Bio Therapeutic Drugs